BETA Technologies launches IPO of 25 million shares priced $27-$33
On Thursday, H.C. Wainwright reiterated a Buy rating on Liquidia Technologies (NASDAQ:LQDA) with a steady price target of $29.00, well within the broader analyst range of $20-$35. The stock, which has surged nearly 50% over the past six months and currently commands a market capitalization of $1.26 billion, has caught significant investor attention. The firm’s analyst, Andrew S. Fein, focused on the company’s progress with its product Yutrepia, an inhaled dry-powder formulation of treprostinil. According to InvestingPro analysis, while the company shows strong momentum, current valuations suggest the stock may be trading above its Fair Value. Fein noted that the launch of Yutrepia is anticipated in the second quarter of 2025, following the end of Tyvaso DPI’s regulatory exclusivity on May 23, 2025.
Fein’s comments highlighted a significant milestone for Liquidia, as the Supreme Court in fall 2024 declined to review a competitor’s appeal concerning the ’793 patent. This decision effectively cleared Yutrepia’s path to full approval for treatment of pulmonary arterial hypertension (PAH). However, the ’327 patent, which pertains to the product’s use for pulmonary hypertension associated with interstitial lung disease (PH-ILD), is still pending. A trial concerning this patent is scheduled for June 2025.
The analyst expressed a positive outlook on the legal standing of Liquidia regarding the ’327 patent, drawing a parallel to the recently invalidated ’793 patent. Fein’s reaffirmation of the Buy rating and price target reflects confidence in Liquidia’s legal position and the potential market opportunity for Yutrepia upon its anticipated launch.
Liquidia Technologies is preparing for the commercial introduction of Yutrepia and is navigating the legal landscape to secure its place in the market for PAH treatments. Analysts tracked by InvestingPro project substantial revenue growth for FY2025, with sales expected to nearly triple. The company’s stock rating and price target by H.C. Wainwright remain unchanged as it approaches key dates in its product’s approval and patent litigation processes. For deeper insights into LQDA’s growth prospects and comprehensive analysis, investors can access the detailed Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Liquidia Technologies reported its financial results for the fourth quarter of 2024, revealing a net loss and revenue figures that fell short of analyst expectations. The company posted an earnings per share (EPS) of -$0.45, missing the forecast of -$0.3821, while revenue reached $2.92 million, below the anticipated $4.54 million. For the full year, Liquidia’s revenue decreased to $14 million from $17.5 million in 2023, and the net loss widened to $130.4 million compared to $78.5 million the previous year. Despite these results, the company remains optimistic about its future prospects, particularly with plans to launch its key product, Eutrepia, in May 2025. Raymond (NSE:RYMD) James maintained a Strong Buy rating for Liquidia, with a price target of $27, citing the anticipated launch of Eutrepia as a significant factor. The firm also highlighted Liquidia’s preparedness for the potential approval and sales activities for the product. Additionally, Liquidia secured $100 million in financing to support its strategic initiatives, including the launch of Eutrepia. These developments underscore the company’s continued efforts to strengthen its position in the market amidst ongoing challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.